Clinical Trial Update: Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating single ascending subcutaneous doses of Exendin 9-39 in individuals with post-bariatric hypoglycemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Post-bariatric Hypoglycemia

Drugs mentioned

• Exendin 9-39 (exendin-9-39)

Snippet

Sponsor: Tracey McLaughlin | Conditions: Hyperinsulinemia Hypoglycemia | Phase 1 | Status: COMPLETED